具有APOE e4等位基因的老年人中含量和认知衰退:一项初步研究
Shin Gyeom Kim1, Young Min Choe2, Guk-Hee Suh2
1Department of Neuropsychiatry, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Republic of Korea.
Psychiatry research
|August 14, 2023
概括
血清含量会影响认知,特别是在具有阿波利波蛋白E ε4 (APOE4) 基因的个体中. 较高的与APOE4载体的记忆和认知得分较低有关,这表明阿尔茨海默病风险中的基因环境相互作用.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 遗传学 遗传学 是一个
背景情况:
- 是一种重要的微量元素,对各种生物功能至关重要.
- 认知能力下降是神经退行性疾病 (如阿尔茨海默氏症) 的标志.
- 阿波利波蛋白E ε4 (APOE4) 基因基因是阿尔茨海默氏症的重要遗传风险因素.
研究的目的:
- 调查血清含量与非痴呆症患者的认知功能之间的关联.
- 为了确定阿波利波蛋白E ε4 (APOE4) 基因型是否能缓和血清和认知之间的关系.
- 探索-APOE4相互作用对阿尔茨海默病风险的影响.
主要方法:
- 一项涉及164名非痴呆症参与者的横截面研究.
- 对血清含量进行评估.
- 综合认知评估包括情节性记忆,执行功能,注意力,语言,视觉空间技能和总认知分数.
主要成果:
- 血清水平和APOE4状态之间在情节性记忆得分 (EMS) 和总得分 (TS) 上观察到显著的相互作用效应.
- 在APOE4阳性的参与者中,血清含量与EMS和TS相反相关.
- 在APOE4阴性参与者中,血清和认知评分之间没有显著的关联.
结论:
- APOE4基因型在血清和认知功能之间的关系中起着至关重要的调节作用.
- 不平衡可能是认知障碍的危险因素,特别是在APOE4载体中.
- 未来的阿尔茨海默病研究应该考虑含量与APOE4状态之间的相互作用.
更多相关视频
相关概念视频
01:26Alzheimer's Disease: Overview
521
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
521
01:23Role of Neurotransmitters in Memory
628
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
628
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
155
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
155
01:30Dementia
139
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
139
01:30Cognitive Development During Adulthood
157
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
157
01:22Alzheimer's Disease: Treatment
215
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
215